Literature DB >> 22085645

Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

Lifeng Cai1, Chungen Pan, Liang Xu, Yuan Shui, Keliang Liu, Shibo Jiang.   

Abstract

We previously reported that the combinatorial use of T20 and T1144, the first and next generations of HIV fusion inhibitors, containing different functional domains resulted in synergistic anti-HIV-1 effect, but this effect diminished when T20 and T1144 were covalently linked together. To elucidate the mechanism underlying this synergistic anti-HIV-1 effect, we studied the interactions between T20 and T1144 either in a mixture state or in a covalently linked state. T20 alone in solution was largely featureless, while T1144 alone was in α-helical trimeric conformation. When mixed in solution, T20 and T1144 showed a loose and transient interaction, with a moderate 10% α-helical content increase, but this interaction was greatly enhanced in the linked state, and T20 and T1144 showed ∼100% α-helical content. These results suggested that the loose and transient interaction between T20 and T1144 may destabilize the T1144 trimer, which makes its otherwise shielded binding sites more accessible to N-terminal heptad repeat (NHR) and increases its associating rate, thus increasing its anti-HIV-1 potency against the temporarily exposed target in NHR and causing the synergistic anti-HIV-1 effect. However, the strong interaction between T20 and T1144 in the covalently linked state may shield their NHR-binding sites, resulting in reduction of the synergistic effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22085645      PMCID: PMC3289504          DOI: 10.1096/fj.11-195289

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

Review 1.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.

Authors:  Shinya Oishi; Saori Ito; Hiroki Nishikawa; Kentaro Watanabe; Michinori Tanaka; Hiroaki Ohno; Kazuki Izumi; Yasuko Sakagami; Eiichi Kodama; Masao Matsuoka; Nobutaka Fujii
Journal:  J Med Chem       Date:  2008-01-16       Impact factor: 7.446

3.  Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.

Authors:  Hiroki Nishikawa; Shota Nakamura; Eiichi Kodama; Saori Ito; Keiko Kajiwara; Kazuki Izumi; Yasuko Sakagami; Shinya Oishi; Tadayasu Ohkubo; Yuji Kobayashi; Akira Otaka; Nobutaka Fujii; Masao Matsuoka
Journal:  Int J Biochem Cell Biol       Date:  2008-09-10       Impact factor: 5.085

4.  Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.

Authors:  Ming-xin Dong; Jian Zhang; Xu-qing Peng; Hong Lu; Liu-hong Yun; Shibo Jiang; Qiu-yun Dai
Journal:  Eur J Med Chem       Date:  2010-06-09       Impact factor: 6.514

5.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

6.  Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.

Authors:  Jie Liu; Yiqun Deng; Qunnu Li; Antu K Dey; John P Moore; Min Lu
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

7.  Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.

Authors:  Lifeng Cai; Edina Balogh; Miriam Gochin
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

8.  SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.

Authors:  Takeshi Naito; Kazuki Izumi; Eiichi Kodama; Yasuko Sakagami; Keiko Kajiwara; Hiroki Nishikawa; Kentaro Watanabe; Stefan G Sarafianos; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

9.  Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.

Authors:  Chungen Pan; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

10.  Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Authors:  Kristen M Kahle; H Kirby Steger; Michael J Root
Journal:  PLoS Pathog       Date:  2009-11-26       Impact factor: 6.823

View more
  6 in total

1.  Generation of a long-acting fusion inhibitor against HIV-1.

Authors:  Ye Guo; Pan-Pan Zhou; Sen-Yan Zhang; Xiao-Wen Fan; Yu-Wei Dou; Xuan-Ling Shi
Journal:  Medchemcomm       Date:  2018-06-06       Impact factor: 3.597

2.  De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.

Authors:  Chao Wang; Lei Zhao; Shuai Xia; Tianhong Zhang; Ruiyuan Cao; Guodong Liang; Yue Li; Guangpeng Meng; Weicong Wang; Weiguo Shi; Wu Zhong; Shibo Jiang; Keliang Liu
Journal:  J Med Chem       Date:  2018-09-19       Impact factor: 7.446

Review 3.  Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.

Authors:  Fei Yu; Lu Lu; Lanying Du; Xiaojie Zhu; Asim K Debnath; Shibo Jiang
Journal:  Viruses       Date:  2013-01-11       Impact factor: 5.048

4.  Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection.

Authors:  Chao Wang; Xue Li; Fei Yu; Lu Lu; Xifeng Jiang; Xiaoyu Xu; Huixin Wang; Wenqing Lai; Tianhong Zhang; Zhenqing Zhang; Ling Ye; Shibo Jiang; Keliang Liu
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

5.  An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications.

Authors:  Wenqing Lai; Chao Wang; Fei Yu; Lu Lu; Qian Wang; Xifeng Jiang; Xiaoyu Xu; Tianhong Zhang; Shengming Wu; Xi Zheng; Zhenqing Zhang; Fangting Dong; Shibo Jiang; Keliang Liu
Journal:  Chem Sci       Date:  2015-12-03       Impact factor: 9.825

6.  Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.

Authors:  Chen Yuan; Jia-Ye Wang; Hai-Jiao Zhao; Yan Li; Di Li; Hong Ling; Min Zhuang
Journal:  Retrovirology       Date:  2019-12-03       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.